Patents Represented by Attorney GlaxoSmithKline
  • Patent number: 8192747
    Abstract: This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate, wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment or rotavirus associated diseases in humans.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: June 5, 2012
    Assignee: GlaxoSmithKline Biologicals, s.a.
    Inventor: Vincent Vande Velde
  • Patent number: 7858098
    Abstract: This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV16 and HPV 18 virus like particles provides cross-protection against other HPV types.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: December 28, 2010
    Assignee: GlaxoSmithKline Biologicals, s.a.
    Inventors: Gary Dubin, Bruce Innis, Moncef Mohammed Slaoui, Martine Anne Cecile Wettendorff
  • Patent number: 7815915
    Abstract: The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: October 19, 2010
    Assignee: GlaxoSmithKline Biologicals, s.a.
    Inventor: Martine Anne Cecile Wettendorff
  • Patent number: 7790179
    Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: September 7, 2010
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Brigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Georges Thiry, Vincent Vande Velde
  • Patent number: 7790180
    Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: September 7, 2010
    Assignee: Glaxosmithkline Biologicals SA
    Inventors: Brigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Georges Thiry, Vincent Vande Velde
  • Patent number: 7758866
    Abstract: An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of the at least one other cancer types is reduced relative to that of HPV 16 or 18.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: July 20, 2010
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Serge Debrus, Marie-Therese Martin, Robert John Stephen, Jean Stephenne, Martine Anne Cecile Wettendorff
  • Patent number: 7655235
    Abstract: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventor: Peter Franz Ertl
  • Patent number: 7579008
    Abstract: The invention provides a method of inducing an immune response against rotavirus infection from one rotavirus serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a different serotype. There is in particular provided a method of inducing an immune response against rotavirus infection from a non-G1 serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a G1 serotype.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: August 25, 2009
    Assignee: GlaxoSmithKline Biologicals, s.a.
    Inventors: Brigitte Desiree Alberte Colau, Beatrice Arsene Virginie De Vos